Quidel Stock Price, News & Analysis

QuidelOrtho Corporation (Nasdaq: QDEL) announced preliminary revenue results for the first quarter of 2023, with total revenues expected to be between $840 million and $850 million. Respiratory product revenue is projected at $262 million to $267 million, which includes $212 million to $217 million from COVID-19 products. Non-respiratory product revenue is forecasted to be $578 million to $583 million, reflecting a 5% increase on a combined basis. This growth was primarily driven by the Labs business unit, aided by a $21 million settlement related to a collaboration agreement. The Company will report full financial results and conduct a conference call on May 3, 2023.

QuidelOrtho Corporation (Nasdaq: QDEL) has announced the formation of the QuidelOrtho Women’s Leadership Network (QWLN), celebrating Women’s History Month. This global network includes 14 leaders and 16 chapters worldwide, focusing on mentoring and empowerment for women. The initiative stems from the merger of Quidel Corporation and Ortho Clinical Diagnostics in 2022, aiming to enhance professional development. CEO Douglas Bryant emphasized the network's role in fostering personal and professional growth. The QWLN offers various programs, including training and community events, to unite women across regions.